Article
Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Cancer research - 1 May 1990
Weil-Hillman G, Voss S D, Fisch P, Schell K, Hank J A, Sosman J A, Sugamura K, Sondel P M
Abstract excerpt
Interleukin 2 (IL-2) induced activation of unstimulated resting natural killer (NK) cells or resting T-cells initially occurs following binding of IL-2 through the p75 receptor that is expressed primarily by these cells. However, this IL-2/p75 interaction induces TAC chain synthesis and formation...
Topics
- Antibodies, Monoclonal
- Antigens, Differentiation, T-Lymphocyte
- CD3 Complex
- CD56 Antigen
- Dose-Response Relationship, Drug
- Humans
- Interleukin-2
- Killer Cells, Lymphokine-Activated
- Lymphocyte Activation
- Phenotype
- Receptors, Antigen, T-Cell
- Receptors, Interleukin-2